Summary
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism: a Cochrane review
Meixuan Li1-3, Jing Li1,2, Xiaoqin Wang4, Xu Hui1,2, Qi Wang3, Shitong Xie3,5, Peijing Yan6, Jinhui Tian1,2, Jianfeng Li7, Ping Xie7, Kehu Yang1,2, Liang Yao3
Affiliation of the authors
1Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China. 2Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China. 3Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canada. 4Michael G DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, Canada. 5School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China. 6Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China. 7Department of Cardiology, Gansu Provincial Hospital, Lanzhou, China.
DOI
Quote
Li M, Li J, Wang X, Hui X, Wang Q, Xie S, et al. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism: a Cochrane review. Emergencias. 2025;37:382-3